
|Articles|December 1, 2004
Formularies shift quickly as Vioxx drops off the market
The Sept. 30 Voluntary Recall of Vioxx (rofecoxib) by Merck is just another in a long list of headline-making news for the industry. The action was based on the results of a three-year, randomized double-blind trial that indicated that after taking Vioxx for 18 months, patients had twice the risk of heart attack compared with a placebo.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
LucyRx and Abarca to merge
2
Hospitals facing financial headwinds can't afford to ignore the mounting threats to 340B
3
FDA approves new sunscreen ingredient, first time in 20 years
4
Updated COVID-19 vaccine cut hospitalization risk by 35% in 2024-2025 season
5
































